Articles
Page 8 of 20
-
Citation: BMC Pharmacology 2009 9(Suppl 1):P79
-
Determination of new phosphorylation sites within natriuretic peptide receptors using mass spectrometric methods
Citation: BMC Pharmacology 2009 9(Suppl 1):P75 -
Pharmacological characterization of receptor guanylyl cyclase reporter cell lines
Citation: BMC Pharmacology 2009 9(Suppl 1):P73 -
Stimulation of soluble guanylate cyclase accelerates renal recovery following relief of unilateral ureteral obstruction
Citation: BMC Pharmacology 2009 9(Suppl 1):P71 -
Blockade of CNG channels abrogates urethral relaxation induced by soluble guanylate cyclase activation
Citation: BMC Pharmacology 2009 9(Suppl 1):P69 -
The role of cGMP-cGKI-signaling for duodenal bicarbonate secretion
Citation: BMC Pharmacology 2009 9(Suppl 1):P67 -
Quantitation of cyclic dinucleotides by reversed-phase LC-MS/MS
Citation: BMC Pharmacology 2009 9(Suppl 1):P65 -
The degree of natriuretic peptide system activation in stable and high risk CHF characterized by increased cystatin C is not reflected in cGMP activation
Citation: BMC Pharmacology 2009 9(Suppl 1):P63 -
The neuronal PDE2A3 splice variant is targeted to membranes via dual acylation
Citation: BMC Pharmacology 2009 9(Suppl 1):P61 -
Antihypertrophic actions of NO-independent soluble guanylyl cyclase (sGC) ligands BAY 41-2272 and BAY 58-2667 in vitro
Citation: BMC Pharmacology 2009 9(Suppl 1):P59 -
Nucleotidyl cyclase activity of recombinant soluble guanylyl cyclase
Citation: BMC Pharmacology 2009 9(Suppl 1):P57 -
Synthesis and characterization of NS-2028 analogues
Citation: BMC Pharmacology 2009 9(Suppl 1):P55 -
Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension
Citation: BMC Pharmacology 2009 9(Suppl 1):P52 -
Thrombospondin-1 is a universal inhibitor of soluble guanylate cyclase activation
Citation: BMC Pharmacology 2009 9(Suppl 1):P50 -
Negative feedback regulation within NO/cGMP pathway attenuates vasodilatory response in renovascular hypertension
Citation: BMC Pharmacology 2009 9(Suppl 1):P48 -
Quantification of cGMP in human plasma by isotope dilution LC-MS/MS
Citation: BMC Pharmacology 2009 9(Suppl 1):P46 -
Pro-B-Type natriuretic peptide: a novel, specific biomarker for detection of left ventricular dysfunction in the general community
Citation: BMC Pharmacology 2009 9(Suppl 1):P44 -
A role for cGMP-dependent protein kinase II in AMPA receptor trafficking and synaptic plasticity
Citation: BMC Pharmacology 2009 9(Suppl 1):S44 -
Identification of novel target proteins of cGMP/cAMP signaling pathway using cGMP/cAMP capture compound mass spectrometry (CCMS)
Citation: BMC Pharmacology 2009 9(Suppl 1):P42 -
Structural insights into sGC
Citation: BMC Pharmacology 2009 9(Suppl 1):S42 -
cGMP kinase I regulates glucagon release
Citation: BMC Pharmacology 2009 9(Suppl 1):P40 -
Differential effects of selective PDE5 inhibitors in rat cerebral arteries in vitro and in vivo
Citation: BMC Pharmacology 2009 9(Suppl 1):P38 -
Structural and mechanistic insights into cGMP signaling
Citation: BMC Pharmacology 2009 9(Suppl 1):S38 -
cGMP-dependent signaling pathways in spinal pain processing
Citation: BMC Pharmacology 2009 9(Suppl 1):S37 -
BAY 58-2667, an NO-independent guanylyl cyclase activator, pharmacologically post-conditions rabbit and rat hearts
Citation: BMC Pharmacology 2009 9(Suppl 1):P36 -
Progressive decline in circulating CNP with aging is associated with progressive cardiac fibrosis and myocardial impairment
Citation: BMC Pharmacology 2009 9(Suppl 1):S35 -
The ANP/cGMP/cGMP-dependent protein kinase pathway counteracts Angiotensin II-stimulated calcium mobilization in cardiac myocytes
Citation: BMC Pharmacology 2009 9(Suppl 1):P34 -
Cardiac natriuretic peptides inhibit TRPC6-mediated prohypertrophic signaling through cGMP-PKG pathway
Citation: BMC Pharmacology 2009 9(Suppl 1):P32 -
Cardio-renal protection of riociguat (BAY 63-2521) in low- and high-renin models of hypertension
Citation: BMC Pharmacology 2009 9(Suppl 1):P30 -
Regulation of soluble guanylyl cyclase by phosphorylation
Citation: BMC Pharmacology 2009 9(Suppl 1):S29 -
GAF domain-induced activation of phosphodiesterases 2 and 5
Citation: BMC Pharmacology 2009 9(Suppl 1):P28 -
A molecular view of the regulation of sGC activity
Citation: BMC Pharmacology 2009 9(Suppl 1):S27 -
Distinct molecular requirements for activation or stabilization of soluble guanylyl cyclase upon haem oxidation-induced degradation
Citation: BMC Pharmacology 2009 9(Suppl 1):P26 -
Presynaptic cGMP-dependent protein kinase-I mediates synaptic potentiation in spinal amplification of pain
Citation: BMC Pharmacology 2009 9(Suppl 1):S25 -
Lack of mechanical and thermal allodynia, and thermal hyperalgesia induced by peripheral neuropathic pain in NOS2 knockout mice
Citation: BMC Pharmacology 2009 9(Suppl 1):P24 -
Role of cGMP-dependent protein kinases for fear memory formation in the lateral amygdala
Citation: BMC Pharmacology 2009 9(Suppl 1):S21 -
Forget cooperativity! – single-molecule signalling with cGMP
Citation: BMC Pharmacology 2009 9(Suppl 1):S19 -
Evaluation of ODQ as specific inhibitor of NO-sensitive guanylyl cyclase using mice deficient for the enzyme
Citation: BMC Pharmacology 2009 9(Suppl 1):P18 -
GMP-mediated regulation of cardiovascular Ca2+ entry channel TRPC6 and its pathophysiological implications
Citation: BMC Pharmacology 2009 9(Suppl 1):S17 -
Rescue of cGMP kinase I and the cause of premature death
Citation: BMC Pharmacology 2009 9(Suppl 1):S15 -
sGC activators and stimulators attenuate ischemia/reperfusion injury of the lung
Citation: BMC Pharmacology 2009 9(Suppl 1):P13 -
Acute heart failure syndromes
Citation: BMC Pharmacology 2009 9(Suppl 1):S13 -
Cardiovascular and gastrointestinal function of IRAG
Citation: BMC Pharmacology 2009 9(Suppl 1):P11 -
The role of cGMP and PKG in cardioprotection
Citation: BMC Pharmacology 2009 9(Suppl 1):S9 -
Mutation of three amino acids in the disulfide-ring of a CNP based chimeric natriuretic peptide alters its vascular properties
Citation: BMC Pharmacology 2009 9(Suppl 1):P8 -
cGMP effects on vascular tone: modulating the activity of myosin light chain phosphatase
Citation: BMC Pharmacology 2009 9(Suppl 1):S7 -
The first crystal structure of cyclic GMP-dependent protein kinase Iβ dimerization/docking domain reveals molecular details of isoform-specific anchoring
Citation: BMC Pharmacology 2009 9(Suppl 1):P6 -
Physiological roles of cGMP-gated channels: lessons from mouse models and human channelopathies
Citation: BMC Pharmacology 2009 9(Suppl 1):S5 -
Cyclic nucleotide phosphodiesterases – 40 years of progress
Citation: BMC Pharmacology 2009 9(Suppl 1):S3 -
Manipulating the natriuretic peptide system for the treatment of pulmonary hypertension
Citation: BMC Pharmacology 2009 9(Suppl 1):P2